Jci_page_head_homepage_01 Jci_page_head_homepage_02
Eui-Cheol Shin, Ulrike Seifert, Takanobu Kato, Charles M. Rice, Stephen M. Feinstone, Peter-M. Kloetzel, Barbara Rehermann
Published in Volume 116, Issue 11
J Clin Invest. 2006; 116(11):3006–3014 doi:10.1172/JCI29832
Abstract | Full text | PDF | Supplemental material
Options: View larger image (or click on image)
Medium
Figure 1
Type I IFN induces the expression of immunoproteasome subunits in vitro.

(A) Huh-7 cells were treated with 3 ng/ml IFN-α–con1 (squares) or 10 ng/ml (200 U/ml) IFN-γ (triangles) for the indicated time periods, after which the mRNA levels of immunoproteasome subunits were quantified by real-time PCR. mRNA levels were normalized to endogenous references (GAPDH and β-actin) and expressed as fold increase over pretreatment levels. The β7 subunit was measured as a control. (B) Huh-7 cells were treated with the indicated doses of IFN-α–con1 or IFN-γ for 48 hours, and Western blot analysis was performed to detect immunoproteasome subunits. The α4 subunit was analyzed as a control. (C) Primary human hepatocytes were treated with 3 ng/ml IFN-α–con1 or 10 ng/ml IFN-γ for the indicated time periods prior to Western blot analysis. (D) Huh-7 cells were treated with 1.8 ng/ml (500 U/ml) IFN-α2a, 3 ng/ml IFN-α–con1, 3 ng/ml IFN-β, or 10 ng/ml IFN-γ for the indicated time periods, and Western blot analysis was performed to detect immunoproteasome subunits. The density of the Western blot bands was quantified and expressed as percent of the density of the α4 control band.